ClinicalTrials.gg
CompletedNCT05058105Updated Sep 27, 2021

Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)

A Phase 1 interventional study of FL058 500mg and Meropenem 1000mg( IV 120min) and FL058 Placebo and Meropenem 1000mg( IV 120min) in Healthy, sponsored by Qilu Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-27.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Oct 2020, registered Sep 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of FL058 and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults aged between 18 and 45 years (inclusive).
  2. (BMI) ranges from 19 to 26 kg/m2 (inclusive), and the body weight is ≥50kg.
  3. Good general health as determined by the Investigator based on medical history, physical examination, vital signs, 12-lead and clinical laboratory tests.
  4. Provide voluntary written prior to any study procedures and are willing and able to comply with the prescribed treatment protocol and evaluations.

Exclusion criteria

Exclusion Criteria:

  1. Concurrent or history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, respiratory, psychiatric, neurologic and/or hematological disorders.
  2. Positive screen result for , -Ab, or -Ab at screening.
  3. History of clinically significant food or drug allergy.
  4. A corrected using Fridericia's formula >450 msec.
  5. \<90mL/min/1.73m2.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    FL058 500mg and Meropenem 1000mg

    FL058 500mg and Meropenem 1000mg (8 subjects); FL058 Placebo and Meropenem 1000mg(2 subjects)

    Drug: FL058 500mg and Meropenem 1000mg( IV 120min) · Drug: FL058 Placebo and Meropenem 1000mg( IV 120min)

  • Experimental
    FL058 1000mg and Meropenem 1000mg

    D1 FL058 1000mg(8 subjects) and FL058 Placebo(2 subjects); D4 Meropenem 1000mg(8 subjects) and Meropenem Placebo(2 subjects); D7\~ D15 FL058 1000mg and Meropenem 1000mg (8 subjects); FL058 Placebo and Meropenem 1000mg(2 subjects)

    Drug: FL058 1000mg( IV 120min) · Drug: FL058 Placebo ( IV 120min) · Drug: Meropenem 1000 mg ( IV 120min) · Drug: Meropenem Placebo ( IV 120min) · Drug: FL058 1000mg and Meropenem 1000mg ( IV 120min) · Drug: FL058 Placebo and Meropenem 1000mg ( IV 120min)

  • Experimental
    FL058 1000mg and Meropenem 2000mg (IV 120min)

    FL058 1000mg and Meropenem 2000mg (8 subjects); FL058 Placebo and Meropenem 2000mg(2 subjects)

    Drug: FL058 1000mg and Meropenem 2000mg ( IV 120min) · Drug: FL058 Placebo and Meropenem 2000m( IV 120min)

  • Experimental
    FL058 1000mg and Meropenem 2000mg (IV 180min)

    FL058 1000mg and Meropenem 2000mg (8 subjects); FL058 Placebo and Meropenem 2000mg(2 subjects)

    Drug: FL058 1000mg and Meropenem 2000mg ( IV 180min) · Drug: FL058 Placebo and Meropenem 2000m( IV 180min)

  • Experimental
    FL058 2000mg and Meropenem 2000mg

    FL058 2000mg and Meropenem 2000mg (8 subjects); FL058 Placebo and Meropenem 2000mg(2 subjects)

    Drug: FL058 2000mg and Meropenem 2000mg( IV 180min) · Drug: FL058 Placebo and Meropenem 2000mg( IV 180min)

Interventions

  • DrugFL058 500mg and Meropenem 1000mg( IV 120min)

    Drug page: Pralurbactam

    D1 qd; D2\~ D8 q8h; D9 qd

  • DrugFL058 Placebo and Meropenem 1000mg( IV 120min)

    D1 qd; D2\~ D8 q8h; D9 qd

  • D1 qd;

  • DrugFL058 Placebo ( IV 120min)

    D1 qd;

  • D4 qd;

  • DrugMeropenem Placebo ( IV 120min)

    D4 qd;

  • DrugFL058 1000mg and Meropenem 1000mg ( IV 120min)

    Drug page: Pralurbactam

    D7 qd; D8\~ D14 q8h; D15 qd;

  • DrugFL058 Placebo and Meropenem 1000mg ( IV 120min)

    D7 qd; D8\~ D14 q8h; D15 qd;

  • DrugFL058 1000mg and Meropenem 2000mg ( IV 120min)

    Drug page: Pralurbactam

    D1 qd; D2\~ D8 q8h; D9 qd

  • DrugFL058 Placebo and Meropenem 2000m( IV 120min)

    D1 qd; D2\~ D8 q8h; D9 qd

  • DrugFL058 1000mg and Meropenem 2000mg ( IV 180min)

    Drug page: Pralurbactam

    D1 qd; D2\~ D8 q8h; D9 qd

  • DrugFL058 Placebo and Meropenem 2000m( IV 180min)

    D1 qd; D2\~ D8 q8h; D9 qd

  • DrugFL058 2000mg and Meropenem 2000mg( IV 180min)

    Drug page: Pralurbactam

    D1 qd; D2\~ D8 q8h; D9 qd

  • DrugFL058 Placebo and Meropenem 2000mg( IV 180min)

    D1 qd; D2\~ D8 q8h; D9 qd

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events [Safety and Tolerability]

    Time frame: Day 1 to Day 24

07

Study locations

1 site
  • Huashan Hospital affiliated to Fudan University
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Feb 2021, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2021
First posted
Sep 27, 2021
StartActual
Oct 8, 2020
Primary completionActual
Feb 24, 2021
CompletionActual
Feb 24, 2021
Last update
Sep 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05058105
Responsible party
Sponsor
First posted
Sep 27, 2021
Start date
Oct 8, 2020
Primary completion
Feb 24, 2021
Completion
Feb 24, 2021
Last update
Sep 27, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralurbactam

Start the discussion